Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intrinsa aftershocks?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

BioSante will meet with FDA in the first quarter to discuss the status of its female sexual dysfunction product LibiGel, the firm said upon announcement of P&G's withdrawal of its FSD patch Intrinsa. BioSante is planning to begin Phase III trials of its testosterone gel. Other firms have been counting on Intrinsa to pave the way for their FSD submissions (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002760

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel